Becker Muscular Dystrophy - Pipeline Review, H1 2018

  • ID: 4473090
  • Drug Pipelines
  • 46 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Italfarmaco SpA
  • Milo Biotechnology LLC
  • PTC Therapeutics Inc
  • ReveraGen BioPharma Inc
  • Sarepta Therapeutics Inc
  • MORE
Becker Muscular Dystrophy - Pipeline Review, H1 2018

Summary:

This latest Pharmaceutical and Healthcare disease pipeline guide Becker Muscular Dystrophy - Pipeline Review, H1 2018, provides an overview of the Becker Muscular Dystrophy (Genetic Disorders) pipeline landscape.

Becker muscular dystrophy (BMD) is one of type of muscular dystrophy, a group of genetic, degenerative diseases primarily affecting voluntary muscles. Symptoms include pain and sensation, difficulty with running, hopping, and jumping, toe walking, breathing problems, cognitive problems and frequent falls.

Report Highlights:

Pharmaceutical and Healthcare latest pipeline guide Becker Muscular Dystrophy - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Becker Muscular Dystrophy (Genetic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Becker Muscular Dystrophy (Genetic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Becker Muscular Dystrophy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 1, 3, 1 and 2 respectively.

Becker Muscular Dystrophy (Genetic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Becker Muscular Dystrophy (Genetic Disorders).
  • The pipeline guide reviews pipeline therapeutics for Becker Muscular Dystrophy (Genetic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Becker Muscular Dystrophy (Genetic Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Becker Muscular Dystrophy (Genetic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Becker Muscular Dystrophy (Genetic Disorders)
Reasons to Purchase:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Becker Muscular Dystrophy (Genetic Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Becker Muscular Dystrophy (Genetic Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Italfarmaco SpA
  • Milo Biotechnology LLC
  • PTC Therapeutics Inc
  • ReveraGen BioPharma Inc
  • Sarepta Therapeutics Inc
  • MORE
Introduction

Report Coverage

Becker Muscular Dystrophy - Overview

Becker Muscular Dystrophy - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Becker Muscular Dystrophy - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Becker Muscular Dystrophy - Companies Involved in Therapeutics Development

Italfarmaco SpA

Milo Biotechnology LLC

PTC Therapeutics Inc

ReveraGen BioPharma Inc

Sarepta Therapeutics Inc

Becker Muscular Dystrophy - Drug Profiles

AAV1-Follistatin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Antisense Oligonucleotide to Inhibit Myostatin for DMD and Becker MD - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ARM-210 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ataluren - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

epicatechin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

givinostat - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

vamorolone - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Becker Muscular Dystrophy - Dormant Projects

Becker Muscular Dystrophy - Product Development Milestones

Featured News & Press Releases

Jun 30, 2015: Cardero Therapeutics Presents at 2015 Parent Project Muscular Dystrophy Connect Conference

Mar 31, 2015: Cardero Therapeutics Presents at 2015 Muscular Dystrophy Association Scientific Conference

Sep 30, 2014: Becker Trial completed at UC-Davis on the Cardero Therapeutics lead compound

May 31, 2013: Becker Trial initiated at UC-Davis on the Cardero Therapeutics lead compound

Mar 31, 2013: Completed triglyceride trial with Cardero Therapeutics lead compound

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables:

Number of Products under Development for Becker Muscular Dystrophy, H1 2018

Number of Products under Development by Companies, H1 2018

Products under Development by Companies, H1 2018

Number of Products by Stage and Target, H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Becker Muscular Dystrophy - Pipeline by Italfarmaco SpA, H1 2018

Becker Muscular Dystrophy - Pipeline by Milo Biotechnology LLC, H1 2018

Becker Muscular Dystrophy - Pipeline by PTC Therapeutics Inc, H1 2018

Becker Muscular Dystrophy - Pipeline by ReveraGen BioPharma Inc, H1 2018

Becker Muscular Dystrophy - Pipeline by Sarepta Therapeutics Inc, H1 2018

Becker Muscular Dystrophy - Dormant Projects, H1 2018

List of Figures:

Number of Products under Development for Becker Muscular Dystrophy, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products by Targets, H1 2018

Number of Products by Stage and Targets, H1 2018

Number of Products by Mechanism of Actions, H1 2018

Number of Products by Stage and Mechanism of Actions, H1 2018

Number of Products by Routes of Administration, H1 2018

Number of Products by Stage and Routes of Administration, H1 2018

Number of Products by Molecule Types, H1 2018

Number of Products by Stage and Molecule Types, H1
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Italfarmaco SpA
  • Milo Biotechnology LLC
  • PTC Therapeutics Inc
  • ReveraGen BioPharma Inc
  • Sarepta Therapeutics Inc
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll